Navigation Links
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Date:2/1/2010

RICHMOND, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, February 8, 2010 at the 12th Annual BIO CEO & Investor Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neu
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
3. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
4. Sangamo Announces Pricing of Public Offering of Common Stock
5. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
6. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
7. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
8. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
9. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
11. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... (Amex:,SGN) and Athletes for Life Foundation announced that ... and screening at the Pontotoc,Technology Center in Ada, ... and a founder of the Athletes for Life ... in a children,s health,education program sponsored by the ...
... BSP Ltd.,( http://www.bsp.co.il/pressall.asp ) an Israeli company which ... of Ischemic Heart,Disease, announced that they successfully raised ... existing shareholders in the company as well,as new ... technology that offers,highly reliable, low-cost and risk free ...
... Leading a trend of unprecedented,growth in biotechnology ... significant traction in the past year in,terms of ... study released,today at the 2008 BIO International Convention ... report support the need to measure,innovation in the ...
Cached Biology Technology:Signalife Announces AFL Joins NIH Education Program 2Signalife Announces AFL Joins NIH Education Program 3BSP Raises $2.6 Million Dollars From Private Investors 2In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 2In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 3In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 4In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 5
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... suggest that policy makers examine greenhouse gas (GHG) ... sources must be rapidly replaced by windmills, solar ... recommendations could be used to help policy makers ... will optimize greenhouse gas emission reductions., "The energy ...
... scientists from Princeton University and The Cancer Institute of New ... the secret lives of cancer cells that go dormant and ... produce new cancer therapies to stem changes that render cancer ... know: What role is this self-cannibalization playing in the middle ...
... aerospace and ocean engineering at Virginia Tech, is the latest ... a National Science Foundation (NSF) Faculty Early Career Development (CAREER) ... 70 Virginia Tech CAREER award winners, of which some 60 ... award was created in 1994. He will receive some $400,000 ...
Cached Biology News:Queen's researchers propose rethinking renewable energy strategy 2Research team targets self-cannibalizing cancer cells 2Research team targets self-cannibalizing cancer cells 3Research team targets self-cannibalizing cancer cells 4Research team targets self-cannibalizing cancer cells 5Engineer studies tensional integrity of biological structures 2Engineer studies tensional integrity of biological structures 3
Mouse Nodal Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Biology Products: